Bristol Launches Zeposia For MS, Sees Advantages In The COVID-19 Environment

After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.